| Value | ₹185.0 Cr |
|---|
BSE filing, NSE: VIYASH. Summary written from the filing by ALFA Finder's alert engine.
Viyash Scientific Ltd: key numbers
- Share price
- ₹224.55
- Market cap
- ₹9,920 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 58.0×Sector 48.7×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.
Viyash Scientific Capital Structure Change
White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.
Viyash Scientific Other Announcement
Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,35,880 ESOP shares at exercise prices of Rs. 86 and Rs. 101. The allotment reflects employee stock option exercises under two active schemes.
Viyash Scientific Acquisition Worth ₹193.4 Cr
Viyash Scientific's subsidiary completed the acquisition of BioForLife Italia s.r.l. for a total consideration of Rs.193.41 Crore. This transaction was previously announced in June.
- Value
- ₹193.4 Cr
Viyash Scientific Acquisition Worth ₹18.33 Cr
Viyash Scientific's subsidiary completed the acquisition of Italy-based BioForLife Italia S.r.l. for a total consideration of approximately EUR 16.98 million.
- Value
- ₹18.33 Cr
Other credit rating announcements
All →Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.